Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps. The study aims to evaluate the efficacy, safety, and tolerability of Itepekimab, an anti-IL-33 monoclonal antibody, in treating chronic rhinosinusitis with nasal polyps.
The study involves testing Itepekimab in two dosing regimens, administered subcutaneously, alongside intranasal corticosteroids. The goal is to determine its effectiveness as an add-on therapy for patients with this condition.
This interventional study is randomized and uses a parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused.
The study began on February 6, 2025, with primary completion expected within 52 weeks of treatment and an additional 20-week safety follow-up. The last update was submitted on June 25, 2025, indicating ongoing recruitment.
The outcome of this study could significantly impact the stock performance of Regeneron and Sanofi, as successful results may enhance their market position in treating chronic rhinosinusitis. Investors should watch for updates, as positive results could influence investor sentiment and competitive dynamics within the pharmaceutical industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.